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BACKGROUND
Morbidity from asthma is disproportionately higher among black patients than among 
white patients, and black patients constitute the minority of participants in trials inform-
ing treatment. Data indicate that patients with inadequately controlled asthma benefit 
more from addition of a long-acting beta-agonist (LABA) than from increased gluco-
corticoids; however, these data may not be informative for treatment in black patients.
METHODS
We conducted two prospective, randomized, double-blind trials: one involving children 
and the other involving adolescents and adults. In both trials, the patients had at least 
one grandparent who identified as black and had asthma that was inadequately con-
trolled with low-dose inhaled glucocorticoids. We compared combinations of therapy, 
which included the addition of a LABA (salmeterol) to an inhaled glucocorticoid (flu-
tic asone propionate), a step-up to double to quintuple the dose of fluticasone, or both. 
The treatments were compared with the use of a composite measure that evaluated 
asthma exacerbations, asthma-control days, and lung function; data were stratified 
according to genotypic African ancestry.
RESULTS
When quintupling the dose of fluticasone (to 250 μg twice a day) was compared with 
adding salmeterol (50 μg twice a day) and doubling the fluticasone (to 100 μg twice a 
day), a superior response occurred in 46% of the children with quintupling the flutica-
sone and in 46% of the children with doubling the fluticasone and adding salmeterol 
(P = 0.99). In contrast, more adolescents and adults had a superior response to the addi-
tion of salmeterol than to an increase in the fluticasone (salmeterol–low-dose flutica-
sone vs. medium-dose fluticasone, 49% vs. 28% [P = 0.003]; salmeterol–medium-dose 
fluticasone vs. high-dose fluticasone, 49% vs. 31% [P = 0.02]). Neither the degree of 
African ancestry nor baseline biomarkers predicted a superior response to specific treat-
ments. The increased dose of inhaled glucocorticoids was associated with a decrease 
in the ratio of urinary cortisol to creatinine in children younger than 8 years of age.
CONCLUSIONS
In contrast to black adolescents and adults, almost half the black children with 
poorly controlled asthma had a superior response to an increase in the dose of an 
inhaled glucocorticoid and almost half had a superior response to the addition of a 
LABA. (Funded by the National Heart, Lung, and Blood Institute; BARD ClinicalTrials 
.gov number, NCT01967173.)
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I nhaled glucocorticoids are effec-tive first-line therapies for asthma control, but when asthma remains poorly controlled, the 
recommended treatment is the addition of a long-
acting β2-adrenergic receptor agonist (LABA).
1-9 
However, this recommendation is based on stud-
ies that included few patients who identified as 
black and does not account for differences in 
genetic ancestry.
Epidemiologic studies involving patients with 
asthma in the United States show a disproportion-
ately greater burden of asthma (exacerbations, 
asthma-related urgent-care visits, hospitalizations, 
and deaths) in persons identified as “black” than 
in those identified as “white.”10-17 Although these 
disparities in asthma morbidity may be due to so-
cial, environmental, or cultural factors, such trends 
persist even after adjustment for contextual fac-
tors for which race or ethnic group may serve as 
surrogates.13-15,18 Studies show that black patients 
often have differential responses to medications 
for asthma, and they have more glucocorticoid 
resistance, less cellular sensitivity to glucocorti-
coids, and more eosinophilic inflammation during 
inhaled glucocorticoid treatment than do white 
patients.19,20 Furthermore, the response to pharma-
cotherapy for asthma can be affected by genetic 
variants that are distributed differentially among 
persons of diverse self-described races and ances-
tral backgrounds; these variants may contribute to 
differences between black patients and white pa-
tients with respect to the response to β2-agonists 
and inhaled glucocorticoids.21-27
Contrary to the findings in white patients,4-8 
a subanalysis involving black patients in one study 
indicated that adding a LABA was not superior to 
increasing the dose of an inhaled glucocorticoid 
in persons who identify as black.8 In addition, a 
follow-up analysis showed that this finding oc-
curred in black children with eczema.28 Further-
more, a retrospective study involving black adults 
suggested that the addition of LABAs may not 
confer the same benefit as an increased dose of 
inhaled glucocorticoids.29
We conducted two parallel Best African Amer-
ican Response to Asthma Drugs (BARD) trials to 
determine the preferred “step-up” strategy in chil-
dren, adolescents, and adults who had at least one 
grandparent who identified as black. We further 
examined the extent to which biomarkers, patient 
characteristics, and ancestral informative genom-
ic variation were predictive of a response to inhaled 
glucocorticoids or LABAs.
Me thods
Overview of the Trials
We conducted two prospective, randomized, dou-
ble-blind, four-treatment, four-period, 56-week 
crossover trials. One trial involved children (5 to 
11 years of age) with at least one grandparent 
who identified as black, and the other involved 
adolescents and adults who were 12 years of age 
or older and who had family backgrounds that 
were similar to those of the children. Patients in 
both trials had inadequately controlled asthma 
while receiving a low-dose inhaled glucocorticoid 
(fluticasone propionate at a dose of 50 μg twice 
daily in children and 100 μg twice daily in ado-
lescents and adults) (Fig. S1 in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org).
In the trial involving children, we compared 
the efficacy of doubling the dose of an inhaled 
glucocorticoid (fluticasone propionate) to a dose 
of 100 μg, administered twice daily (the double-
fluticasone group); doubling the dose of flutica-
sone to 100 μg and adding a LABA (salmeterol) 
at a dose of 50 μg (the salmeterol–double-flutica-
sone group); quintupling the dose of fluticasone 
to 250 μg (the quintuple-fluticasone group); or 
quintupling the dose of fluticasone to 250 μg and 
adding salmeterol at a dose of 50 μg (the salmet-
erol–quintuple-fluticasone group). Owing to the 
lack of a low-dose inhaled glucocorticoid–LABA 
combination (i.e., salmeterol–fluticasone propio-
nate, both at a dose of 50 μg), we could not ex-
amine the effect of merely adding salmeterol to 
the baseline dose of inhaled glucocorticoid.
In the trial involving adolescents and adults, 
we compared the efficacy of adding twice-daily 
salmeterol at a dose of 50 μg to baseline twice-
daily administration of f luticasone propionate 
at a dose of 100 μg (the salmeterol–fluticasone 
group); increasing the dose of fluticasone by a fac-
tor of 2.5 to 250 μg (the 2.5-fluticasone group); 
quintupling the dose of fluticasone to 500 μg (the 
quintuple-fluticasone group); or increasing the 
dose of fluticasone by a factor of 2.5 to 250 μg and 
adding salmeterol at a dose of 50 μg (the salmet-
erol–2.5-fluticasone group).
The trials were identical in design and step-up 
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dosing strategies. However, the first step-up regi-
men was different in the two trials because of the 
above-described differences in available formula-
tions for children.
Oversight of the Trials
The trial was funded by the National Heart, Lung, 
and Blood Institute (NHLBI) and approved by the 
AsthmaNet steering committee, an NHLBI-appoint-
ed protocol review committee, and a data and 
safety monitoring board. The authors vouch for 
the accuracy and completeness of the data, for the 
accuracy of the analyses, and for the fidelity of 
the trial to the protocol (available at NEJM.org). 
GlaxoSmithKline donated the medications for the 
trials but did not have any other role in the design 
of the trials, in the collection or interpretation of 
the data, or in the preparation of the manuscript.
Patients
Patients of both sexes who were 5 years of age 
or older and who reported having or (in the case 
of children) were reported by a parent or guardian 
as having at least one black grandparent were 
recruited from nine AsthmaNet partnership sites. 
The patients had a baseline forced expiratory vol-
ume in 1 second (FEV1) of at least 40% of the 
predicted value after bronchodilator use (after four 
puffs of albuterol [90 μg per puff]) as well as a 
diagnosis of asthma confirmed by beta-agonist 
reversibility (an increase in the FEV1 of at least 
12%), a methacholine provocation concentration 
causing a 20% decrease (PC20) in the FEV1 of 16 mg 
per milliliter or less, or an absolute difference in 
the percentage of the predicted FEV1 of at least 
12 percentage points over two measurements 
documented within the previous year (Section 1 in 
the Supplementary Appendix).
Run-in Period
Patients who were receiving an inhaled glucocor-
ticoid or an inhaled glucocorticoid–LABA combi-
nation were included in the trials, except for those 
who had inadequately controlled asthma while 
they were receiving a high-dose inhaled gluco-
corticoid–LABA. The run-in period consisted of an 
open-label inhaled glucocorticoid (fluticasone pro-
pionate at a dose of 50 μg twice daily in children 
and fluticasone propionate at a dose of 100 μg 
twice daily in patients who were at least 12 years 
of age). Patients could undergo randomization if 
they were found to have inadequately controlled 
asthma within 2 to 10 weeks after they entered 
the run-in period (Section 2 in the Supplementary 
Appendix).
Treatment Periods
Patients who met the randomization criteria (Sec-
tion 2 in the Supplementary Appendix) were ran-
domly assigned to step-up treatment sequences in 
a four-way crossover design with add-on LABA, 
different strengths of increased doses of inhaled 
glucocorticoid, or an increased dose of inhaled 
glucocorticoid with LABA in dry-powder Diskus 
inhalers (Fig. S1 in the Supplementary Appen-
dix). Each treatment period lasted 14 weeks. The 
initial 2 weeks of each period were considered to 
be a washout period for the previous treatment and 
a wash-in period for the new regimen. Data on 
asthma-control days during those 2 weeks were 
censored from the analyses.
Primary Outcomes
The primary aims of these trials were to evaluate 
the superiority of different treatments and the ef-
fect of the proportion of African ancestry (as in-
formed by ancestry informative markers as de-
tailed below) on the composite clinical outcome. 
The primary clinical outcome of each trial was a 
hierarchical composite measure that sequentially 
evaluated asthma exacerbations (Section 3 in the 
Supplementary Appendix), asthma-control days, 
and the percentage of the predicted FEV1 at the 
end of the 14-week treatment regimens to deter-
mine a differential response.8 A treatment was 
deemed to be superior to another if there was a 
between-treatment differential response of at least 
one exacerbation, defined as worsening asthma 
events leading to treatment with systemic gluco-
corticoids or unscheduled health care utilization. 
If no exacerbation difference was identified, a dif-
ferential of 31 annualized asthma-control days was 
evaluated, and if no differential in asthma-con-
trol days was identified, then an absolute differ-
ence of 5 percentage points in the percentage of 
the predicted FEV1 was evaluated. (The primary 
and prespecified comparisons are described in 
Section 7 in the Supplementary Appendix.)
Whole-blood DNA was genotyped with the use 
of Illumina Multi-Ethnic Global Array BeadChips 
and 117,053 informative single-nucleotide poly-
morphisms (linkage disequilibrium, r2≥0.1) select-
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ed for estimation of genetic ancestry. Genotype 
data were analyzed with 225 HapMap founders 
representing founders with ancestry from north-
ern and western Europe (described in the Centre 
d’Etude du Polymorphisme Humain HapMap sam-
ples) and central west Africa (Yoruba) (http://ftp 
. ncbi . nlm . nih . gov/ hapmap/ ) and 43 Native Ameri-
cans to estimate the percentage of African, Euro-
pean, and Native American ancestry in each pa-
tient.30-32 Ancestry-based genetic analyses evaluated 
the association of the percentage of African ances-
try with the primary composite outcome (Section 7 
and Fig. S6 in the Supplementary Appendix).
Secondary Outcomes
Secondary outcomes included asthma-control days 
(according to the use of albuterol rescue, use of 
glucocorticoids, symptoms, unscheduled office 
visits, and peak flows that were <90% of the ref-
erence value determined during the run-in period 
for each patient) (Section 3 in the Supplementary 
Appendix); the FEV1, before or after bronchodila-
tor use; and measures of asthma control. Asthma 
control was also assessed with the use of the 
Childhood Asthma Control Test (in which scores 
range from 0 [uncontrolled] to 27 [well controlled], 
with a minimally important difference of 2) and 
the Asthma Control Test (in which scores range 
from 5 [uncontrolled] to 25 [well controlled], with 
a minimally important difference of 3); higher 
values represent better asthma control in both 
instruments. Quality of life was assessed with 
the use of the Asthma Quality of Life Question-
naire (AQLQ) (in which scores range from 1 to 
7 and higher scores represent less impairment, 
with a minimally important difference of 0.5).
Exploratory Outcomes
The number and type of asthma exacerbations 
(i.e., visits to the emergency department and hos-
pitalizations) were evaluated. Patient characteris-
tics, including atopy, pulmonary function (e.g., the 
degree of bronchodilator reversibility and the de-
gree of methacholine responsiveness), and selective 
biomarkers, (e.g., sputum eosinophils) were exam-
ined to evaluate the differential response to trial 
treatments.
Systemic Effects
Overnight urine specimens were obtained for mea-
surements of the ratio of cortisol to creatinine at 
baseline and after treatment intervals. Recent data 
from the AsthmaNet Step Up Yellow Zone Inhaled 
Corticosteroids to Prevent Exacerbations trial33 
showed a reduced linear growth rate associated 
with the use of high-dose glucocorticoids among 
children younger than 8 years of age, so we ana-
lyzed data stratified according to ages younger 
than 8 years and 8 years or older.
Statistical Analysis
In the primary analysis, the target sample size of 
284 children and 291 adolescents and adults had 
90% power with a two-sided alpha of 0.05 to iden-
tify an absolute difference of 20 percentage points 
in the percentage of patients with a superior re-
sponse to one therapy over another for the com-
posite asthma outcome, assuming a withdrawal 
rate of 20% among children and 35% among 
adults before complete trial data acquisition. This 
analysis modeled the probability of patients hav-
ing a superior response to one specific treatment 
over another, defined according to the composite 
outcome. The composite outcome and its compo-
nents were fit with the use of nonlinear mixed-
effect models for each pair of treatment compari-
sons (Section 7 in the Supplementary Appendix).34,35
In the trial involving children (5 to 11 years 
of age), the primary prespecified comparison was 
between fluticasone propionate at a dose of 250 μg 
twice daily (quintuple fluticasone) and twice-daily 
fluticasone propionate at a dose of 100 μg plus 
salmeterol at a dose of 50 μg (salmeterol–double 
fluticasone). In the trial involving adolescents and 
adults, we were able to directly examine step-up 
regimens with a LABA as compared with in-
creased doses of a glucocorticoid (at two doses), 
and we prespecified two primary comparisons: 
fluticasone propionate at a dose of 250 μg twice 
daily (2.5-fluticasone) versus twice-daily flutica-
sone at a dose of 100 μg plus salmeterol at a dose 
of 50 μg (salmeterol–fluticasone), and twice-daily 
fluticasone at a dose of 500 μg (quintuple flutica-
sone) versus twice-daily fluticasone at a dose of 
250 μg plus salmeterol at a dose of 50 μg (sal-
meterol–2.5-fluticasone), without adjustment for 
multiple testing. (Section 7 in the Supplementary 
Appendix lists prespecified secondary compari-
sons of the other dose combinations.) The re-
sults of the trial involving children and those of 
the trial involving adults and adolescents were 
also compared.
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R esult s
Baseline Characteristics of the Patients
Between January 2014 and March 2016, a total of 
280 children (of 482 enrolled) and 294 adoles-
cents and adults (of 536 enrolled) underwent 
randomization at nine centers (Figs. S2 and S3 
and Table S1 in the Supplementary Appendix). 
The majority of children were male, and the 
majority of adolescents and adults were female 
(Table 1). As compared with the adolescents and 
adults, more children had a blood eosinophil count 
of at least 300 cells per cubic millimeter, and 
children had a higher percentage of the predicted 
FEV1, more courses of systemic glucocorticoids, 
and more unscheduled office visits and hospital-
izations because of asthma in the previous year. 
(Complete baseline characteristics of the patients 
and of those who completed the trials as compared 
with those who discontinued the trials are provid-
ed in Table S1 in the Supplementary Appendix.)
Outcomes in Children
The majority of children had a differential outcome 
between treatments. The maximum percentage of 
patients who did not have a superior response in 
any paired intervention comparison was 12% 
(Fig. 1). There was no significant difference in 
the probability of a superior response when the 
dose of inhaled glucocorticoid was increased two 
steps to a quintupled dose of fluticasone propio-
nate (250 μg) (46% superior) as compared with 
a two step-up strategy of adding a LABA (salmet-
erol) at a dose of 50 μg and increasing the dose 
of fluticasone to 100 μg (46% superior) (P = 0.99) 
(Fig. 1B).
In children, 53% of patients (95% confidence 
interval [CI], 45 to 61) in the salmeterol–double-
fluticasone group had a superior response, as 
compared with 41% (95% CI, 33 to 49) in the 
double-fluticasone group (Fig. 1A), whereas 43% 
(95% CI, 35 to 52) in the salmeterol–quintuple-
fluticasone group had a superior response, as 
compared with 47% (95% CI, 39 to 56) in the the 
quintuple-fluticasone group (Fig. 1C). A total of 
51% of patients (95% CI, 42 to 59) had a superior 
response to a higher dose of inhaled glucocorti-
coid (in the quintuple-fluticasone group) as com-
pared with 37% of patients (95% CI, 29 to 45) who 
had a superior response to a lower dose of inhaled 
glucocorticoid (in the double-fluticasone group) 
(Fig. 1E). (Differential responses to increasing the 
dose of inhaled glucocorticoid as compared with 
adding a LABA in the elements of the composite 
of FEV1, asthma-control days, or exacerbations 
are shown in Figures S4.1 through S4.3 in the 
Supplementary Appendix.)
Outcomes in Adolescents and Adults
In all the comparisons in the trial involving ado-
lescents and adults, 20 to 25% of the patients did 
not have a differential outcome between treat-
ments (Fig. 2). More adolescents and adults had 
a superior response with the addition of a LABA 
than with either of the two step-up dose increas-
es in inhaled glucocorticoids (49% in the salme-
terol–fluticasone group vs. 28% in the 2.5-fluti-
casone group) (P = 0.003) (Fig. 2A), and 49% in 
the salmeterol–2.5-fluticasone group versus 31% 
in the quintuple-f luticasone group (P = 0.02) 
(Fig. 2C). Differences in superior response rates 
were driven by differences in asthma-control days 
and FEV1 (Figs. S5.2A and S5.2B and S5.3A and 
S5.3B in the Supplementary Appendix). Exacer-
bations were infrequent and contributed only 
minimally to the composite outcome (Fig. S5.1.A 
and S5.1.B in the Supplementary Appendix). In-
creasing the dose of glucocorticoid by either a 
factor of 2.5 (fluticasone propionate at a dose of 
250 μg) or a factor of 5 (fluticasone propionate 
at a dose of 500 μg) (Fig. 2D) or from 100 μg of 
fluticasone propionate to 250 μg of fluticasone 
propionate (accompanied by a LABA) (Fig. 2E) did 
not result in a significantly higher percentage of 
patients with a superior response.
Comparison of the Two Trials
In adolescents and adults, the addition of a LABA 
was more likely to produce superior responses 
than increasing the dose of an inhaled glucocor-
ticoid. In contrast, children had a response to 
stepped increases in the dose of inhaled glucocor-
ticoid (Fig. 3A, and Figs. S4 and S5 in the Supple-
mentary Appendix).
Secondary Outcomes
The results of prespecified secondary outcomes 
and analyses are provided in Figures S4 and S5 
and Table S8 in the Supplementary Appendix. 
Consistent with the trend seen in the evaluation 
of the composite outcome, more children had re-
duced asthma exacerbations with a higher dose of 
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 (N = 280)
Adolescents and Adults  
(≥12 Yr) 
 (N = 294)
Demographic features
Age — yr 8.5±1.8 37.3±16.1
Male sex — no. (%) 170 (60.7) 95 (32.3)
Median percentage of African ancestry (IQR)† 81.0 (73.4–85.6) 82.1 (75.3–87.6)
Hispanic ethnic group — no. (%)‡ 24 (8.6) 9 (3.1)
Asthma history in previous 12 mo — no. (%)
One or more asthma episodes resulting in emergency care or unscheduled 
office visit
208 (74.3) 132 (44.9)
One or more overnight hospitalizations 43 (15.4) 14 (4.8)
One or more courses of systemic glucocorticoids 172 (61.4) 99 (33.7)
Medications used in previous 12 mo
Leukotriene-receptor antagonist or 5-lipoxygenase inhibitors — no. (%) 107 (38.2) 50 (17.0)
Oral glucocorticoids — no./total no. (%) 170/277 (61.4) 92/293 (31.4)
Inhaled or nebulized glucocorticoid monotherapy — no./total no. (%) 246/279 (88.2) 193/294 (65.6)
Inhaled glucocorticoid–LABA combination therapy — no./total no. (%) 64/279 (22.9) 139 /294 (47.3)
Clinical and spirometric features
Patients with ≥1 of 13 positive tests for allergens by ImmunoCAP assay — 
no./total no. (%)
224/273 (82.1) 244/287 (85.0)
Sputum eosinophil level ≥2% — no./total no. (%)§ NA 24/220 (10.9)
Median blood eosinophil absolute count — cells/mm3 (IQR)¶ 340 (200–510) 200 (100–300)
Median serum total IgE — IU/ml (IQR)‖ 286.5 (92.0–693.5) 174.0 (73.0–468.0)
FEV1 — % of predicted value** 95.5±16.7 83.4±17.4
Bronchodilator response (4 puffs) — % relative change†† 13.79±14.48 12.47±12.43
PC20 for methacholine — mg/ml‡‡
Geometric mean 1.32 1.71
Coefficient of variation 1.61 1.60
Median score on Childhood Asthma Control Test or Asthma Control Test 
(IQR)§§
22 (19–24) 19 (16–22)
Asthma-control days during 2 wk before randomization (%)¶¶ 31.2±29.9 24.5±28.2
*  Plus–minus values are means ±SD. FEV1 denotes forced expiratory volume in 1 second, LABA long-acting beta-agonist, and NA not appli-
cable.
†  Data were missing for 15 children and 10 adolescents and adults.
‡  Race and ethnic group were reported by the patients or their parents or guardians.
§  Children younger than 12 years of age did not undergo sputum induction.
¶  Data were missing for 5 children and 5 adolescents and adults.
‖  Data were missing for 4 children and 4 adolescents and adults.
**  Data were missing for 5 children and 3 adolescents and adults.
††  Data were missing for 7 children.
‡‡  PC20 denotes the provocative concentration of inhaled methacholine that results in a 20% reduction in the FEV1. Data were missing for  
67 children and 44 adolescents and adults.
§§  The score on the Childhood Asthma Control Test ranges from 0 to 27, with higher values representing better asthma control. The score on 
the Asthma Control Test ranges from 5 to 25, with higher values representing better asthma control. Data were missing for 1 patient in 
each group.
¶¶  Patients who provided asthma-control information on fewer than 7 of the 14 days were excluded from this summary, and data were miss-
ing for 3 children and 5 adolescents and adults.
Table 1. Characteristics of the Patients at Baseline.*
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inhaled glucocorticoid (7%; 95% CI, 2 to 13) 
than with a lower-dose of inhaled glucocorticoid 
(2%; 95% CI, 0 to 5). Higher-dose inhaled glu-
cocorticoids also produced greater changes in the 
percentage of the predicted FEV1 before or after 
bronchodilator use (2.3%; 95% CI, 0.7 to 4.0) than 
a lower-dose inhaled glucocorticoid (1.6%; 95% CI, 
0.1 to 3.0).
Adolescents and adults had more asthma-con-
trol days with the addition of a LABA than with 
an increase in the dose of inhaled glucocorticoid 
(a 14-day-per-year difference [95% CI, 1 to 26] in 
the salmeterol–fluticasone group vs. the 2.5-flu-
tic asone group and a 14-day-per-year difference 
[95% CI, 3 to 25] in the salmeterol–2.5-flutica-
sone group vs. the quintuple-fluticasone group) 
(Table S8 in the Supplementary Appendix). There 
was also an absolute difference in the percentage 
of the predicted FEV1 before bronchodilator use 
(the salmeterol–fluticasone group vs. the 2.5-flu-
ticasone group, 1.2 percentage points [95% CI, 
0.2 to 2.3]; and the salmeterol–2.5-fluticasone 
Figure 1. Percentage of Black Children (5 to 11 Years of Age) with Asthma Who Had a Superior Response to Specific Treatments,  
According to the Composite Outcome, at 14 Weeks.
Shown are the five prespecified comparisons of the percentages of patients with a superior response among those receiving twice-daily 
treatment with a low-dose inhaled glucocorticoid (fluticasone propionate) at a dose of 50 μg (FP100, the double-fluticasone group);  
a dose of fluticasone doubled to 100 μg with the addition of a LABA (salmeterol) at a dose of 50 μg (FP100/SM50, the salmeterol–dou-
ble-fluticasone group); a dose of fluticasone quintupled to 250 μg (FP250, the quintuple-fluticasone group); or a dose of fluticasone 
quintupled to 250 μg with the addition of salmeterol at a dose of 50 μg (FP250/SM50, the salmeterol–quintuple-fluticasone group) with 
respect to the hierarchical composite outcome that incorporated asthma exacerbations, asthma-control days, and change in the forced 
expiratory volume in 1 second (FEV1). The numbers in each bar represent the percentage of patients who had a superior response to 
that specific treatment, as compared with the alternative treatment. Gray bars indicate the percentage of patients in whom one treat-
ment was not superior to the other. The P value reflects a test of the coprimary null hypothesis that the probability of a superior response 
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group vs. the quintuple-fluticasone group, 0.9 per-
centage points [95% CI, −0.1 to 1.9]) (Table S8 in 
the Supplementary Appendix). However, the addi-
tion of a LABA did not differentially affect asthma 
exacerbations, the FEV1 after bronchodilator use, 
the results of the Asthma Control Test, or the 
results of the AQLQ.
 Genetic African Ancestry and Therapeutic 
Outcomes
Among patients in both age groups, there was a 
broad distribution in the percentage of African 
ancestry, ranging from 2 to 100%, with a mean 
of 81.0% in children and 82.1% in adolescents 
and adults (Table 1, and Fig. S6 in the Supple-
mentary Appendix); this distribution was com-
parable to that in black populations in previous 
studies.36 There were no significant interactions 
between the percentage of African ancestry and 
the primary composite outcome or any of the in-
dividual outcomes (Tables S2 and S3 in the Sup-
plementary Appendix). We were unable to identify 
a cutoff for the percentage of African ancestry 
that was predictive of therapeutic response (Ta-
bles S4 through S7 in the Supplementary Appen-
dix), and we did not find significant, consistent, 
Figure 2. Percentage of Black Adolescents and Adults with Asthma Who Had a Superior Response to Specific Treatments, According to 
the Composite Outcome, at 14 Weeks.
Shown are all the comparisons of the percentages of patients with a superior response among those receiving twice-daily treatment 
with fluticasone propionate at a dose of 100 μg plus salmeterol at a dose of 50 μg (FP100/SM50, the salmeterol–fluticasone group); 
a dose of fluticasone increased by a factor of 2.5 to 250 μg (FP250, the 2.5-fluticasone group); a dose of fluticasone quintupled to 
500 μg (FP500, the quintuple-fluticasone group); or a dose of fluticasone increased by a factor of 2.5 to 250 μg with the addition of sal-
meterol at a dose of 50 μg (FP250/SM50, the salmeterol–2.5-fluticasone group) with respect to the hierarchical composite outcome 
that incorporated asthma exacerbations, asthma-control days, and the absolute change in the percentage of the predicted FEV1. The 
numbers in each bar represent the percentage of patients who had a superior response to that specific treatment, as compared with the 
alternative treatment. Gray bars indicate the percentage of patients in whom one treatment was not superior to the other. The P values 
reflect a test of the coprimary null hypotheses that the probability of a superior response to each treatment would not differ. T bars in-






































































































































































The New England Journal of Medicine 
Downloaded from nejm.org at Washington University in St. Louis Becker Library on October 23, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;13 nejm.org September 26, 2019 1235
Step-Up Ther apy in Black Patients with Asthma
meaningful associations between African ances-
try and the treatment response when the extremes 
of ancestry were compared (Figs. S7.1 and S7.2 in 
the Supplementary Appendix).
For the primary composite outcome in both 
trials, none of the prespecified biomarkers or pa-
tient characteristics identified a group of patients 
who were more likely to have a response to the 
addition of one therapy than to another.
 Safety
In the trial involving children, the highest dose of 
inhaled glucocorticoid (250 μg twice daily) was 
associated with a decrease in the ratio of urinary 
cortisol to creatinine in those who were younger 
than 8 years of age (Table S9 in the Supplementary 
Appendix), whereas no such effects were seen in 
adolescents and adults. There were no other sig-
nificant differences among the treatment groups 
Figure 3. Comparison of the Primary Composite Outcome in the Trial involving Adolescents and Adults and the Trial involving Children.
Shown are the prespecified comparisons of the percentages of patients with a superior response. Each panel shows a comparison of a 
similar step-up in therapy for children and for adolescents and adults. Shown are responses at 14 weeks in adolescents and adults and 
in children who at baseline had poorly controlled asthma while receiving twice-daily treatment with a low-dose inhaled glucocorticoid 
(fluticasone propionate) (50 μg in children and 100 μg in adolescents and adults). In children, the step-up trial treatments included 
doubling the dose of fluticasone to 100 μg (FP100, the double-fluticasone group); doubling the dose of fluticasone to 100 μg and adding 
salmeterol at a dose of 50 μg (FP100/SM50, the salmeterol–double-fluticasone group); quintupling the dose of fluticasone to 250 μg 
(FP250, the quintuple-fluticasone group); or quintupling the dose of fluticasone to 250 μg and adding salmeterol at a dose of 50 μg 
(FP250/SM50, the salmeterol–quintuple-fluticasone group). In adolescents and adults, the step-up interventions included adding sal-
meterol to the baseline dose of fluticasone (FP100/SM50, the fluticasone–salmeterol group), increasing the dose of fluticasone by a fac-
tor of 2.5 (FP250, the 2.5-fluticasone group), increasing the dose of fluticasone by a factor of 2.5 and adding salmeterol (FP250/SM50, 
the salmeterol–2.5-fluticasone group), or quintupling the dose of fluticasone (FP 500). A superior response was determined with re-
spect to the hierarchical composite outcome that incorporated asthma exacerbations, asthma-control days, and the change in the FEV1. 
The numbers in each bar represent the percentage of patients who had a superior response to that specific treatment as compared with 
the alternative treatment. Gray bars indicate the percentage of patients in whom one treatment was not superior to the other. The two 
groups of patients (patients from the trial involving children and those from the trial involving adolescents and adults) were compared 
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in either trial with respect to respiratory tract in-
fections or pneumonia.
Discussion
Studies involving children and adults with asthma 
have been conducted primarily in white popula-
tions; these studies have shown that when esca-
lating asthma therapy, the addition of a LABA is 
more likely to produce a superior response than 
an increase in the dose of an inhaled glucocor-
ticoid.5-8 These data have influenced guidelines 
regarding escalation of therapy when patients 
present with asthma that is not well controlled; 
however, black patients with asthma have not 
been included in the clinical trials on which the 
guidelines were based.10,11,13-16
In the current trials, almost half the children 
who had at least one grandparent who identified 
as black and who had poorly controlled asthma 
(46%) had improved asthma outcomes when the 
dose of inhaled glucocorticoid was increased rath-
er than with the addition of a LABA. Furthermore, 
we discovered that in contrast to both black 
adults and white adults and white children, black 
children had a response to stepped increases in 
the dose of inhaled glucocorticoid. Our results 
are all the more striking in that in our parallel 
trial we confirmed that adolescents and adults 
who had at least one grandparent who identified 
as black had responses similar to those reported 
in white adults — that is, the addition of a LABA 
in adults was more likely to lead to superior re-
sponses in a larger group of patients than an 
increase in the dose of an inhaled glucocorti-
coid. These findings suggest that data cannot be 
extrapolated from clinical trials involving mixed 
populations to specific subgroups, including those 
of different ages and races.
We found that larger percentages of children 
than had been previously reported in mixed popu-
lations had a response to increasing doses of 
glucocorticoids than to the addition of a LABA.8 
Although a recent trial involving predominantly 
white children with mild-to-moderate persistent 
asthma showed that quintupling the dose of in-
haled glucocorticoids for 7 days at the early signs 
of loss of asthma control was not better in pre-
venting exacerbations than maintaining the use 
of low-dose inhaled glucocorticoids,33 that trial 
involved short-term administration of higher-dose 
inhaled glucocorticoids in patients with acute de-
terioration of asthma and thus is not comparable 
to our trials examining the effects of long-term 
treatment.
We found evidence of adrenal axis suppression 
in young children (<8 years of age) (Table S9 in 
the Supplementary Appendix) at the highest dose 
of inhaled glucocorticoid we tested (fluticasone 
propionate at a dose of 250 μg). Our trial was not 
long enough to assess effects on growth. However, 
the findings with regard to the adrenal axis at high 
doses of inhaled glucocorticoids are of potential 
concern, although it is not clear how our find-
ings would extrapolate to other formulations of 
inhaled glucocorticoids.
African ancestry, as determined by patterns of 
genetic markers, has been associated with asthma-
related phenotypes including low lung function 
and exacerbations.36-38 However, we did not find 
that African ancestry was associated with differ-
ential responses in adolescents and adults or with 
differential responses in children (Figs. S7.1 and 
S7.2 in the Supplementary Appendix). Neverthe-
less, the absence of a global ancestral effect does 
not exclude potential effects of either asthma se-
verity loci or pharmacogenetic loci differentially 
inherited among persons across varying ances-
tral backgrounds.21-27 We were also not able to de-
tect phenotypic or biomarker characteristics that 
were associated with a differential response to a 
specific therapy. A larger trial might have the 
power to determine which phenotypic or specific 
pharmacogenetic variant panels could have the 
power to detect such differences.
In conclusion, our prospective, randomized 
BARD trials comparing several strategies of treat-
ment escalation for asthma in children and in ado-
lescents and adults who had at least one grandpar-
ent who identified as black showed that outcomes 
differed in children and adults, and the results 
in these children differed from those previously 
reported in studies involving white children. In 
contrast to black adults and white persons of all 
ages, almost half the children who had at least 
one grandparent who identified as black and who 
had poorly controlled asthma had a superior re-
sponse to an increased dose of an inhaled glu-
cocorticoid over the addition of a LABA. A larg-
er, more simplified trial should be undertaken to 
determine the best treatment approach for black 
children with poorly controlled asthma despite 
the use of standard doses of an inhaled gluco-
corticoid.
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